Mechanically-Responsive Synthetic Circuits for Controlled Biologic Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack the ability to effectively utilize mechanical stimuli to drive the production of therapeutic biologics in response to mechanical inputs, which are crucial for various medical conditions and diseases.
Innovation Solution
Development of genetically modified cells equipped with synthetic circuits that link mechanically-responsive genes to therapeutic biologics, allowing for controlled expression of anti-catabolic, anti-inflammatory, pro-anabolic, and anti-pain peptides in response to mechanical stimuli, using viral vectors like adeno-associated or lentiviral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current therapies are used, then treatment is provided, but the ability to utilize mechanical stimuli to drive therapeutic biologic production is lacking
Solution Approach 1:
The patent replaces conventional chemical or physical drug delivery systems with a mechanobiology-based system where mechanical stimuli directly trigger therapeutic biologic production through mechanically-responsive gene circuits, enabling the body's own mechanical forces to drive therapy
Solution Approach 2:
The system enables self-regulated therapeutic production where the mechanical stimuli generated by the body's natural functions (such as joint movement or tissue loading) automatically trigger the production and release of therapeutic biologics without external intervention
2Productivity
If mechanically-responsive cells are engineered, then controlled production of therapeutic biologics is achieved, but device complexity increases
Solution Approach 1:
The patent employs universal promoter elements and standardized genetic circuit components that can be applied across different cell types and therapeutic applications, reducing the need for custom engineering for each specific use case
Solution Approach 2:
The genetic circuit is divided into modular functional components including mechanically-responsive promoters, transcriptional regulators, and therapeutic biologic coding sequences, allowing independent optimization and standardized assembly of each module
3Productivity
If viral vectors are used for gene delivery, then efficient transduction is achieved, but safety and immunogenicity concerns arise
Solution Approach 1:
The patent employs non-integrating viral vectors or transient expression systems that deliver genetic material without permanent integration into the host genome, minimizing long-term safety concerns while maintaining efficient transient transduction for therapeutic production
Solution Approach 2:
The patent uses engineered transcriptional regulators and promoter elements as intermediary components that mediate between the viral vector's genetic material and the host cell's transcription machinery, enabling controlled expression while reducing direct viral integration requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables targeted and controlled production of therapeutic biologics within tissues, enhancing treatment efficacy for conditions such as osteoarthritis, cancer, and inflammatory diseases by leveraging mechanical inputs for drug delivery.
Implementation Method 1
Mechanically sensitive ion channels respond to a mechanical input by altering their conformation between an open state and a closed state thereby initiating mechanotransduction
Implementation Method 2
The nucleic acid sequence can be delivered into a host cell using a viral vector or other suitable delivery system
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions and methods of making genetically modified cells comprising a synthetic circuit that is responsive to a mechanical input to the cell and methods of use thereof. This disclosure uses mechanotransduction to provide gene-based delivery of biologic drugs at prescribed times, phases and frequencies. Once reprogrammed, the cells can be reimplanted in the body for this purpose.